Device Restorative Dentistry

Jeltrate Dustless Alginate Impression Material

Payments companies reported to CMS as associated with Jeltrate Dustless Alginate Impression Material. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$11Kassociated payments (2023-2025)
41clinicians with associated payments
1company reporting

By year

2024 $11K

Payments reported as associated with Jeltrate Dustless Alginate Impression Material, per program year, as reported to CMS.

Who makes it

Specialties most often involved

General Practice (Dentist) $6,690
Dentist $2,573
Orthodontics and Dentofacial Orthopedics $772
Prosthodontics $515

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Jeltrate Dustless Alginate Impression Material

These are the largest totals companies reported as associated with Jeltrate Dustless Alginate Impression Material. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
David Hecht Forked River, NJ General Practice (Dentist) $257.32
Valerie Paul Natrona Heights, PA General Practice (Dentist) $257.32
Randall Ewing San Diego, CA General Practice (Dentist) $257.32
William Devaney Portsmouth, NH General Practice (Dentist) $257.32
Deanna Risos Chula Vista, CA General Practice (Dentist) $257.32
Rolando Martinez Columbus, OH General Practice (Dentist) $257.32
Kristina Snyder Highland Heights, OH General Practice (Dentist) $257.32
Michael Woolbert Shreveport, LA General Practice (Dentist) $257.32
Manuel Cambeiro North Arlington, NJ General Practice (Dentist) $257.32
Christopher Kaplan Mt Freedom, NJ General Practice (Dentist) $257.32

Prescribed Jeltrate Dustless Alginate Impression Material?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.